REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 4 2025 08:46:04 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 4 2025 15:08:52 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 4 2025 08:45:07 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

01 4 2025 13:45:14 提供 NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 3 2025 08:50:37 提供 NetDania Notify

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

28 3 2025 01:00:14 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 3 2025 08:46:28 提供 NetDania Notify

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

25 3 2025 15:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

25 3 2025 13:10:05 提供 NetDania Notify

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

11 3 2025 20:32:16 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

08 3 2025 12:00:00 提供 Nasdaq GlobeNewswire

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

28 2 2025 06:00:02 提供 Nasdaq GlobeNewswire

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

26 2 2025 06:00:19 提供 Nasdaq GlobeNewswire

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

24 2 2025 14:00:04 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

17 2 2025 23:59:00 提供 Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

11 2 2025 15:05:00 提供 Nasdaq GlobeNewswire

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

11 2 2025 06:00:39 提供 Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

08 2 2025 16:40:16 提供 Nasdaq GlobeNewswire

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

08 2 2025 14:55:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

04 2 2025 08:45:06 提供 NetDania Notify